Afuresertib is a potent inhibitor of the AKT kinase pathway, which plays a key role in cell survival, proliferation, and metabolism. It is primarily investigated for its anticancer properties, especially in tumors with hyperactivated PI3K/AKT/mTOR signaling pathways. This includes certain types of breast cancer, ovarian cancer, prostate cancer, and hematologic malignancies such as leukemia and lymphoma. In clinical and preclinical studies, afuresertib has shown the ability to induce apoptosis and inhibit tumor growth, both as a single agent and in combination with other therapies such as chemotherapy, hormonal therapy, or targeted agents like PARP inhibitors. Its application is particularly relevant in cancers with PTEN deficiency or AKT mutations, where pathway overactivation is a driver of disease progression. Due to its mechanism, afuresertib is being evaluated in clinical trials to determine optimal dosing, safety, and efficacy across various solid tumors and blood cancers. It represents a targeted therapeutic strategy aimed at disrupting survival signals in cancer cells, potentially improving outcomes in resistant or advanced disease settings.